Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

被引：0
|
作者：
Ridderstrale, M. [1 ]
Fitchett, D. [2 ]
Kis, S. Giljanovic [3 ]
Woerle, H. J. [4 ]
Mattheus, M. [4 ]
Zinman, B. [5 ]
Inzucchi, S. [6 ]
机构：
[1] Steno Diabet Ctr, Gentofte, Denmark
[2] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[3] Eli Lilly Suisse SA, Representat Off, Zagreb, Croatia
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5803
引用
收藏
页码：1192 / 1192
页数：1
相关论文
共 50 条
  • [1] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [2] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [3] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Fitchett, D.
    Kis, Giljanovic S.
    Woerle, H.
    Zinman, B.
    Inzucchi, S.
    NEPHROLOGY, 2016, 21 : 58 - 58
  • [4] Effect of empagliflozin on nephropathy in subgroups by age: results from EMPA-REG OUTCOME
    von Eynatten, M.
    Bergenstal, R. M.
    Calabro, P.
    Maldonado-Lutomirsky, M.
    Mattheus, M.
    Lachin, J. M.
    Wanner, C.
    DIABETOLOGIA, 2016, 59 : S483 - S483
  • [5] Effect of Empagliflozin on Nephropathy in Subgroups by Age: Results from EMPA-REG Outcome
    Bergenstal, Richard M.
    Calabro, Paolo
    Lutomirsky, Mario Maldonado
    Von Eynatten, Maximillian
    Mattheus, Michaela
    Wanner, John Lachin Christoph
    DIABETES, 2016, 65 : A314 - A314
  • [6] EFFECT OF EMPAGLIFLOZIN ON NEPHROPATHY IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Bergenstal, R.
    Lutomirsky, Maldonado M.
    Wanner, C.
    NEPHROLOGY, 2016, 21 : 59 - 59
  • [7] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [8] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [9] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    Lee, Dae Wook
    Monteiro, Pedro
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
  • [10] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. -J.
    Inzucchi, S. E.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S534
12345